StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.43−0.40 (-10.44%)

Close on Nov 17, 2026Market cap $66.34MP/E –Yield –

Earnings

Kala Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2025
–
EPS, Q2 FY2025
-$1.71
-$3.16 a year earlier
Latest guidance
Reaffirmed
Nov 8, 2022 · 2 items

Quarterly results

Revenue and earnings per share from each of Kala Bio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2025ended Jun 30, 2025Aug 8, 2025before the open––-$1.71Release
Q1 FY2025ended Mar 31, 2025May 14, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025before the open––-$1.74Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open––-$3.16Release
Q1 FY2024ended Mar 31, 2024May 14, 2024during market hours–––Release
Q4 FY2023ended Dec 31, 2023Mar 29, 2024before the open–––Release
Q3 FY2023ended Sep 30, 2023Nov 13, 2023before the open–––Release
Q2 FY2023ended Jun 30, 2023Aug 4, 2023before the open––-$4.36Release
Q1 FY2023ended Mar 31, 2023May 9, 2023before the open––-$6.99Release
Q4 FY2022ended Dec 31, 2022Mar 3, 2023before the open–––Release
Q3 FY2022ended Sep 30, 2022Nov 8, 2022before the open$400.00K-87.1%$19.25Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Kala Bio guided for has been reported

Guidance history

Every forecast Kala Bio put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 8, 2022non-GAAP operating expensesFY2022+50%Reaffirmed
Nov 8, 2022non-GAAP total operating expensesFY2023+60% – +70%Reaffirmed
Aug 11, 2022reduction in non-GAAP operating expensesFY2022+50%New
Aug 11, 2022reduction in non-GAAP total operating expensesFY2023+60% – +70%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Kala Bio filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Results
  3. News
  4. Update
  5. Update
  6. News
  7. News
  8. News
  9. Results
  10. Results
  11. Results
  12. News
  13. Results
  14. Results
  15. News

See a number that looks wrong?